Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therapy after current Phase 2b and Phase 3 candidates have been approved. This conversation considers how the idea that front-line treaters will be PCPs might affect treatment patterns.
Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversation examines the prospect for different kinds of backbone strategies.
Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversation lays out basic premises.
Mazen Noureddin joins the Surfers to explore the issues and needs that will shape treatment guidelines in a world after NASH drugs come to market.
Louise Campbell and Roger Green join co-authors Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gawrieh to discuss why this epidemiology paper from the 2021 Journal of Hepatology is an urgent call to action for NAFLD and NASH screening and treatment.
Louise Campbell and Roger Green join co-authors Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gawrieh in a deeper dive into key findings from the 2021 Journal of Hepatology paper titled “Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.”
Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gawrieh share key findings from their 2021 Journal of Hepatology paper titled “Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.”
Study co-authors Stephen Harrison, Naim Alkhouri and Samer Gawrieh suggest that current estimates of NAFLD and NASH populations in the US may be meaningfully understated.
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to conisder key takeaways from the Congress. This conversation is organized around competing strategies for diagnostic testing as the NASH market evolves.
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to consider key takeaways from the Congress. This conversation is organized around adoption of non-invasive testing in clinical development and when drugs will come to market.
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to conisder key takeaways from the Congress. This conversation is organized around changes in treatment paradigms and guidelines.
The SurfingNASH coverage team from the Fourth Global NASH Congress convenes one more time to consider key takeaways from the Congress. Manal Abdelbalek, Naim Alkhouri, Ian Rowe, Suneil Hosmane, Louise Campbell and Roger Green all share high points, opportunities and lingering questions.
